Project Grant R44TR005899
Award Date 7/1/26
Completion Date 6/30/28
Dollars Obligated $958K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98102, USA
Similar Awards
- Federal Project Grant Award Summary Capienda Biotech, LLC received a $329,272 Project Grant from the National Center for Advancing Translational Sciences (NCATS) under the NCATS program (CFDA 93.350), awarded August 1, 2025, with completion targeted for January 31, 2027. The company is developing a high-throughput kinetic system instrument that enables rapid characterization of small-molecule drug binding kinetics at unprecedented scale. Building on Phase I National Science Foundation (NSF)...
- Project Grant Summary Precision Quantomics, Inc. received a $570,888 Project Grant from the National Center for Advancing Translational Sciences (NCATS) under the NCATS program (CFDA 93.350), awarded on August 15, 2025, with a completion date of August 14, 2026. The project focuses on developing recombinant human enzyme panels that represent genetic variants in drug-metabolizing enzymes relevant to diverse U.S. patient populations. The deliverable addresses a critical gap in current drug...
- Grant Award Summary Goeppert LLC received a $350,000 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded July 1, 2026, with completion scheduled for June 30, 2027. Under this award, Goeppert is developing NANO-PAVE (Nanopore-based Analysis of Proportion of Full and Empty Adeno-Associated Virus Capsids via Nanopore Evaluation), a solid-state nanopore platform designed to assess the quality and potency of adeno-associated viruses (AAVs) used...
- Federal Grant Award Summary Cytoagents Inc. received a $1.31 million Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on September 22, 2025, with completion targeted for August 31, 2027. The award supports the development of CTO1681, an orally available pharmaceutical compound designed to prevent and mitigate cytokine release syndrome (CRS) in multiple myeloma patients undergoing chimeric antigen receptor (CAR) T-cell therapy....
- Federal Project Grant Award Summary Talus Bioscience Inc. received a $1,035,634 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded July 1, 2026, with completion targeted for June 30, 2028. The award funds the deployment and optimization of STRATEGIAN, an artificial intelligence (AI)-powered drug discovery platform designed to accelerate development of transcription factor (TF) therapeutics. Transcription factors regulate gene expression and...
- Celdara Medical, LLC received a $310,564 Project Grant from the National Center for Advancing Translational Sciences (NCATS) under the Translational Research Program (CFDA 93.350), effective July 1, 2026, through June 30, 2027. The award supports the development of engineered regulatory T cells (Tregs) as a therapeutic platform for Gaucher disease, a lysosomal storage disorder characterized by deficiency of the enzyme glucocerebrosidase (GCase). The company is developing constructs to enable...
- Federal Grant Award Summary Syntr Health Technologies, Inc. received a $406,500 Project Grant award from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) on August 15, 2025, with a completion date of August 14, 2027. The award supports the development and commercialization of the SYNTRFUGE, a fully automated centrifugal lab-on-a-chip platform designed to rapidly dissociate solid tumor tissue into single cells for diagnostic analysis. The technology combines...
- Federal Project Grant Award Summary Onca Bio, Inc. received a $697,696 Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350, effective September 15, 2025, through September 14, 2027. The award funds development of segmented in vitro translation (SIVT) technology to enhance mRNA display-based peptide library diversity for drug discovery applications. The project addresses a key limitation in current macrocyclic peptide synthesis, wherein...
- Federal Project Grant Award Summary Cellchorus Inc. received a $399,625 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective September 1, 2025, through August 31, 2027. The award supports the development of functional signatures derived from post-infusion Chimeric Antigen Receptor (CAR) T cells to enable early identification of patient response in relapsed/refractory large B cell lymphoma (R/RLBCL) cases. The primary...
- Cisterna Biologics, Inc. received a $349,746 Project Grant award from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) effective August 1, 2025, through July 31, 2027. Under this Phase I Small Business Innovation Research (SBIR) award, the company is developing and validating an innovative platform technology capable of synthesizing high-quality, purified messenger RNA (mRNA) that eliminates product-related contaminants—specifically double-stranded RNA (dsRNA),...